196 related articles for article (PubMed ID: 16504968)
1. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage.
Barker CR; McNamara AV; Rackstraw SA; Nelson DE; White MR; Watson AJ; Jenkins JR
Nucleic Acids Res; 2006; 34(4):1148-57. PubMed ID: 16504968
[TBL] [Abstract][Full Text] [Related]
2. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.
Yao Q; Weigel B; Kersey J
Clin Cancer Res; 2007 Mar; 13(5):1591-600. PubMed ID: 17332306
[TBL] [Abstract][Full Text] [Related]
3. The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?
Barker CR; Hamlett J; Pennington SR; Burrows F; Lundgren K; Lough R; Watson AJ; Jenkins JR
Int J Cancer; 2006 Jun; 118(11):2685-93. PubMed ID: 16385570
[TBL] [Abstract][Full Text] [Related]
4. Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.
McNamara AV; Barclay M; Watson AJ; Jenkins JR
Biochem Pharmacol; 2012 Feb; 83(3):355-67. PubMed ID: 22138446
[TBL] [Abstract][Full Text] [Related]
5. Heteronemin, a Marine Sesterterpenoid-Type Metabolite, Induces Apoptosis in Prostate LNcap Cells via Oxidative and ER Stress Combined with the Inhibition of Topoisomerase II and Hsp90.
Lee MG; Liu YC; Lee YL; El-Shazly M; Lai KH; Shih SP; Ke SC; Hong MC; Du YC; Yang JC; Sung PJ; Wen ZH; Lu MC
Mar Drugs; 2018 Jun; 16(6):. PubMed ID: 29890785
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol.
Gadelle D; Bocs C; Graille M; Forterre P
Nucleic Acids Res; 2005; 33(7):2310-7. PubMed ID: 15849317
[TBL] [Abstract][Full Text] [Related]
7. 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
Tse AN; Sheikh TN; Alan H; Chou TC; Schwartz GK
Mol Pharmacol; 2009 Jan; 75(1):124-33. PubMed ID: 18820127
[TBL] [Abstract][Full Text] [Related]
8. DNA damage response (DDR) induced by topoisomerase II poisons requires nuclear function of the small GTPase Rac.
Wartlick F; Bopp A; Henninger C; Fritz G
Biochim Biophys Acta; 2013 Dec; 1833(12):3093-3103. PubMed ID: 23999236
[TBL] [Abstract][Full Text] [Related]
9. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
10. Etoposide quinone is a redox-dependent topoisomerase II poison.
Jacob DA; Mercer SL; Osheroff N; Deweese JE
Biochemistry; 2011 Jun; 50(25):5660-7. PubMed ID: 21595477
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin.
Bagatell R; Beliakoff J; David CL; Marron MT; Whitesell L
Int J Cancer; 2005 Jan; 113(2):179-88. PubMed ID: 15455381
[TBL] [Abstract][Full Text] [Related]
12. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
13. Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override.
Beeharry N; Rattner JB; Caviston JP; Yen T
Cell Cycle; 2013 May; 12(10):1588-97. PubMed ID: 23624842
[TBL] [Abstract][Full Text] [Related]
14. N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison.
Bender RP; Lindsey RH; Burden DA; Osheroff N
Biochemistry; 2004 Mar; 43(12):3731-9. PubMed ID: 15035644
[TBL] [Abstract][Full Text] [Related]
15. Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIalpha: altering enzyme function by blocking the N-terminal protein gate.
Bender RP; Lehmler HJ; Robertson LW; Ludewig G; Osheroff N
Biochemistry; 2006 Aug; 45(33):10140-52. PubMed ID: 16906772
[TBL] [Abstract][Full Text] [Related]
16. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
17. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol acts as a topoisomerase II poison in human glioma cells.
Leone S; Basso E; Polticelli F; Cozzi R
Int J Cancer; 2012 Aug; 131(3):E173-8. PubMed ID: 22095529
[TBL] [Abstract][Full Text] [Related]
20. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
